

About Dr. Jianbo Wan,

Dr. Jianbo Wan is currently a Professor of the Institute of Chinese Medical Sciences (ICMS) and State Key Laboratory of Quality Research in Chinese Medicine, University of Macau (UM). Dr. Wan received his Ph.D. in Biomedical Sciences from University of Macau in 2008 and completed his post-doctoral program at Laboratory for Lipid Medicine and Technology in Massachusetts General Hospital, an affiliated hospital of Harvard Medical School during 2009-2011.

Dr. Wan's research interests are *i)* Chemical Derivatization Strategy for Mass Spectrometry-based Lipidomics and Metabolomics; *ii)* Quality Evaluation of Chinese Medicines; *iii)* Pharmacological Study on Chinese Medicines for the Prevention of Metabolic Diseases, including fatty liver. Dr. Wan has published over 180 peer-reviewed SCI papers, including *Nature communications*, *Journal of Advanced Research*, *Redox Biology*, *Journal of Pharmaceutical Analysis*, *Critical Reviews in Food Science and Nutrition*, and *Analytica Chimica Acta*, with a total citation of over 6400 times and an H-index of 44 (web of science). He is acting as Deputy Editor and Editorial office Director of *Chinese Medicine* (IF 4.9), an official journal of ISCM.

Selected publications

1. Ma LJ, Liu X, Guo L, Luo Y, Zhang B, Cui X, Yang K, Cai J, Liu F, Yang FQ, He X, Shi S, **Wan JB***. Discovery of plant chemical defence mediated by a two-component system involving β -glucosidase in *Panax* species. *Nat Comm.*, 2024, in press. **(IF 16.6)**
2. Dai JK, Dan WJ, Cao YD, Gao JX, Wang JR, **Wan JB***. Discovery of new quaternized norharmane dimers as potential anti-MRSA agents. *J Adv Res.* 2023 Nov 4:S2090-1232(23)00328-4**(IF 10.7)**
3. Yang RJ, Zou J, Liu JY, Dai JK, **Wan JB***. Click chemistry-based enrichment strategy for tracing cellular fatty acid metabolism by LC-MS/MS. *J Pharm Anal.* 2023 Oct;13(10):1221-1231. **(IF 8.8)**
4. Zou J, Yang R, Feng R, Liu J, **Wan JB***. Ginsenoside Rk2, a dehydroprotopanaxadiol saponin, alleviates alcoholic liver disease via regulating NLRP3 and NLRP6 inflammasome signaling pathways in mice. *J Pharm Anal.* 2023 Sep;13(9):999-1012. **(IF 8.8)**
5. Tian B, Liu J, Liu Y, **Wan JB***. Integrating diverse plant bioactive ingredients with cyclodextrins to fabricate functional films for food application: a critical review. *Crit Rev Food Sci Nutr.* 2023;63(25):7311-7340. **(IF 10.2)**
6. Feng RB, Li GD; Ko CN, Zhang Z, **Wan JB***, Zhang, QW. Long-Lived Second Near-Infrared Luminescent Probes: An Emerging Role in Time-Resolved Luminescence Bioimaging and Biosensing. *Small Struct.* 2023, 4, 2200131 **(IF 15.9)**
7. Ma LJ, Ma N, Cao JL, **Wan JB***. Characterizing the influence of different drying methods on chemical components of *Panax notoginseng* leaves by heart-cutting two-dimensional liquid

chromatography coupled to orbitrap high-resolution mass spectrometry. Food Chem. 2022 Feb 1;369:130965 (IF 8.8)

8. Li G, Liu H, Feng R, Kang TS, Wang W, Ko CN, Wong CY, Ye M, Ma DL, **Wan JB***, Leung CH*. A bioactive ligand-conjugated iridium(III) metal-based complex as a Keap1-Nrf2 protein-protein interaction inhibitor against acetaminophen-induced acute liver injury. Redox Biol. 2021 Sep 10;102129 (IF 11.4)
9. Zou J, Wang SP, Wang YT, **Wan JB***. Regulation of the NLRP3 inflammasome with natural products against chemical-induced liver injury. Pharmacol Res. 2020 2021; 164: 105388. (IF 9.3)
10. Xia F, He C, Ren M, Xu FG, **Wan JB***. Quantitative profiling of eicosanoids derived from n-6 and n-3 polyunsaturated fatty acids by twin derivatization strategy combined with LC-MS/MS in patients with type 2 diabetes mellitus. Anal Chim Acta. 2020, 1120: 24-35. (IF 6.2)

For more information, please visit the website

(<https://pubmed.ncbi.nlm.nih.gov/?term=wan+jb&sort=pubdate>)

主持基金情况

起止时间	项目名称	经费总额 (RMB)	经费来源	担任角色
2023-01 至 2024.12	基於點擊化學策略的羧基代謝物富集分析方法的構建及II型糖尿病靶向標誌物的發現	456,750	澳门大学研究委员会	项目主持人
2022-01 至 2025.12	三七葉新型葡萄糖苷酶 GH-Pn12Glc介導化學防禦的機制研究及植物源農藥開發	2,183,000	澳门科学技术发展基金	项目主持人
2021-10 至 2024.10	功能模块化光动力药物用于克服非小细胞肺癌旁路激活耐药及序贯疗效监控	142.6	国家自然科学基金-澳门科学技术发展基金联合项目	项目主持人
2019-10 至 2022-10	三七叶质量控制及其安神镇静研究	140.4	澳门科学技术发展基金	项目主持人
2018-10 至 2020-10	长链 Omega-3 多不饱和脂肪酸对乙酰氨基酚诱导的急性肝损伤的改善作用及其机理研究	101.2	澳门科学技术发展基金	项目主持人
2018-06 至 2020-12	中国劲酒质量控制过程中微量成分稳定性与质量标准研究	80.0	劲牌有限公司科研合作	项目主持人
2018-01 至 2020-12	三七叶植物中的酶转化三七叶皂苷及其酒精性肝损伤保护作用的研究	124.2	澳门大学研究委员会	项目主持人
2017-01 至 2019-12	基于 UPLC/Q-TOFMS 代谢组学技术的中药寒热属性研究	66.8	澳门大学研究委员会	项目主持人
2017-01 至 2018-12	水飞蓟-葛根复合物改善酒精性肝损伤的作用机制研究	15.0	汤臣倍健营养科学研究基金	项目主持人
2016-01 至 2018-12	三七中原人参二醇型和原人参三醇型皂苷抗动脉粥样硬化作用及其机制研究	18.0	国家自然科学基金委员会	项目主持人
2015-01 至 2017-12	ZG 治疗骨质疏松的药效物质基础及其作用机制研究	50.0	广东国际合作项目	境外主持人
2015-07 至 2018-06	卡博替尼靶向调控 miR-221/TIMP-2/MMP-2 通路治疗肝细胞癌的作用机制研究	50.0	广东国际合作项目	境外主持人
2014-01 至 2016-12	n-6 与 n-3 脂肪酸的比例对酒精性和非酒精性脂肪肝的影响 (校内配套)	43.8	澳门大学研究委员会	项目主持人
2014-01 至 2016-12	n-6 与 n-3 脂肪酸的比例对酒精性和非酒精性脂肪肝的影响	131.3	澳门科学技术发展基金	项目主持人

2013-06 至 2016-12	内源性 Omega-3 脂肪酸对酒精性 脂肪肝的影响	102.8	澳门大学研究 委员会	项目主 持人
2012-06 至 2015-06	中药三七生物活性成分对血管炎 症及动脉粥样硬化的影响	114.8	澳门大学研究 委员会	项目主 持人